{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.798","value":"-5.50"}]}],"title":"Global Health Status/QoL, Change from BL at EOT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.806","value":"-6.00"}]}],"title":"Physical functioning, Change from BL at EOT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.344","value":"-7.67"}]}],"title":"Role functioning, Change from BL at EOT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.023","value":"-5.00"}]}],"title":"Emotional functioning, Change from BL at EOT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.760","value":"-5.33"}]}],"title":"Cognitive functioning, Change from BL at EOT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.177","value":"-11.33"}]}],"title":"Social functioning, Change from BL at EOT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.695","value":"5.11"}]}],"title":"Fatigue, Change from BL at EOT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.677","value":"3.33"}]}],"title":"Nausea/Vomiting, Change from BL at EOT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.621","value":"5.00"}]}],"title":"Pain, Change from BL at EOT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.970","value":"10.00"}]}],"title":"Dyspnea, Change from BL at EOT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.512","value":"-6.00"}]}],"title":"Insomnia, Change from BL at EOT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.290","value":"4.67"}]}],"title":"Appetite Loss, Change from BL at EOT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.332","value":"2.00"}]}],"title":"Constipation, Change from BL at EOT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.852","value":"6.00"}]}],"title":"Diarrhea, Change from BL at EOT"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.909","value":"4.00"}]}],"title":"Financial Difficulties, Change from BL at EOT"}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"description":"EORTC QLQ-C30 is a patient completed 30 item questionnaire that consists of 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The patient evaluates their health status over the previous week. There are 28 questions answered on a 4-point scale where1=Not at all (best) to 4=Very Much (worst) and 2 questions answered on a 7-point scale where 1=Very poor (worst) to 7= Excellent (best). All of the scales and single-item measures are transformed to a score:0 to 100. For functioning scales and global QOL higher scores indicate better functioning (a positive change from Baseline indicates improvement); for symptom scales higher scores indicate more severe symptoms (a negative change from Baseline indicates improvement).","dispersionType":"Standard Deviation","groups":[{"description":"Ixazomib 4.0 mg, capsules, orally, on Days 1, 8, 15 of a 28-day cycle and cyclophosphamide (CYC) 300 mg/m\\^2, tablets, orally, on Days 1, 8 and 15 of a 28-day cycle and dexamethasone (DEX) 40 mg, tablets, orally, on Days 1, 8, 15 and 22 (dose reduced to 20 mg for patients \\>75 years) of a 28-day cycle until PD/death or unacceptable toxicity in participants with RRMM.","id":"OG000","title":"Ixazomib 4.0 mg + CYC 300 mg/m^2 + DEX 40 mg (RRMM)"}],"paramType":"MEAN","populationDescription":"Participants from the Safety Population, defined as all participants who received at least 1 dose of any study drug, with data available for analysis.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1 of Cycle 1), Day 1 of End of Treatment (EOT) (Up to 45 months)","title":"Change From Baseline in EORTC Quality of Life Questionnaire (QLQ-C30) in RRMM Participants","type":"SECONDARY","unitOfMeasure":"score on a scale"}